Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on the Long-Term Safety and Effectiveness of Losmapimod for Patients with Facioscapulohumeral Muscular Dystrophy (FSHD)

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition called Facioscapulohumeral Muscular Dystrophy (FSHD), which is a genetic disorder that causes muscle weakness, particularly in the face, shoulders, and upper arms. The study is testing a treatment called Losmapimod, which is taken as a film-coated tablet. The purpose of the study is to evaluate the safety and tolerability of long-term use of Losmapimod in individuals with FSHD.

Participants in the study will be randomly assigned to receive either Losmapimod or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. The study will last for 48 weeks, with an option for an open-label extension, where all participants may receive Losmapimod. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment.

The main focus of the study is to ensure that Losmapimod is safe and well-tolerated over a long period. Researchers will also measure the levels of Losmapimod in the blood at regular intervals to understand how the body processes the medication. This study aims to provide valuable information about the potential benefits and safety of Losmapimod for people living with FSHD.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the participant will be required to provide written informed consent. This involves understanding the study details and agreeing to participate.

    Eligibility is confirmed through a genetic test for Facioscapulohumeral Muscular Dystrophy 1 (FSHD1), which must be completed before any further steps.

  2. Step 2

    Screening and baseline assessments

    A screening period of up to four weeks is conducted to confirm eligibility. This includes a clinical severity assessment and an MRI to identify a suitable muscle for biopsy.

    Participants must have a clinical severity score between 2 and 4 and must not require a wheelchair or walker.

  3. Step 3

    Randomization and initial treatment phase

    Participants are randomly assigned to receive either the study drug, losmapimod, or a placebo. This is a double-blind process, meaning neither the participant nor the study team knows which treatment is being administered.

    The medication is provided in the form of a film-coated tablet for oral use.

  4. Step 4

    Treatment administration

    The treatment phase lasts for 48 weeks. Participants take the assigned medication as directed, with regular monitoring of health and any side effects.

    The primary focus is on the safety and tolerability of long-term use of losmapimod.

  5. Step 5

    Open-label extension (OLE)

    After the initial 48-week period, participants may enter an open-label extension phase where all receive losmapimod.

    This phase continues to monitor safety and plasma concentrations of the drug every 12 weeks.

  6. Step 6

    End of study

    The study is estimated to conclude by October 31, 2025. Participants will undergo final assessments to evaluate the long-term effects of the treatment.

    The primary endpoint is the safety and tolerability of losmapimod, while secondary endpoints include measuring drug levels in the blood.

Who can join the trial?

7 criteria

  • Must be able to understand and sign a written consent form.
  • Must be between 18 and 65 years old.
  • Must have a confirmed diagnosis of Facioscapulohumeral Muscular Dystrophy 1 (FSHD1), which is a genetic condition affecting muscles. This confirmation can be from previous tests if verified by a certified lab.
  • Must have a clinical severity score between 2 and 4, which measures the impact of the condition. Cannot use a wheelchair or walker for any activity.
  • Must have a muscle suitable for a biopsy, as determined by a specialist using an MRI scan.
  • Must be willing and able to attend scheduled visits, follow the treatment plan, and adhere to study guidelines, including laboratory tests and contraceptive use.
  • Must agree to use an approved method of birth control during the study and for 90 days after the last dose of the study drug. This applies to both male and female participants.

Who cannot join the trial?

4 criteria

  • Individuals who do not have Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) cannot participate. This is a specific type of muscle disorder.
  • Participants must be within a certain age range, which is not specified here, but if you are outside this range, you cannot join.
  • Both males and females can participate, but if you do not identify as either, you may not be eligible.
  • If you are considered part of a vulnerable population, which means you might need extra protection or care, you may not be able to participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Losmapimod is a medication being studied for its potential to treat facioscapulohumeral muscular dystrophy (FSHD). This condition is a genetic muscle disorder that causes progressive muscle weakness. The trial aims to assess how safe and well-tolerated losmapimod is when taken over a long period by individuals with FSHD. The study is designed to determine if losmapimod can help improve muscle function and slow down the progression of the disease.

What is already known about the treatment

Losmapimod – Losmapimod is administered orally in tablet form. It is currently being studied in clinical trials for its potential use in treating Facioscapulohumeral Muscular Dystrophy 1 (FSHD1). The main therapeutic indication for losmapimod is to improve muscle function and reduce inflammation in patients with FSHD1. At the molecular level, losmapimod works by inhibiting specific enzymes known as p38 MAP kinases, which play a role in the inflammatory response. It is classified pharmacologically as a kinase inhibitor.

Investigated diseases

Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) – This is a genetic muscle disorder characterized by progressive muscle weakness and wasting. It primarily affects the muscles of the face, shoulders, and upper arms. The disease often begins with weakness in the facial muscles, leading to difficulties in smiling, whistling, or closing the eyes. As it progresses, it can cause weakness in the shoulder and upper arm muscles, making it difficult to lift objects or raise the arms. Over time, the weakness may extend to other muscles, including those in the legs and abdomen. The rate of progression and severity can vary widely among individuals.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-512732-30-00Protocol codeFIS-002-2019Estimated enrolment80 patientsSponsorFulcrum Therapeutics Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).